Ursodeoxycholic Acid in Barrett's Endotherapy

Conditions

• Barrett's Esophagus With Dysplasia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

Barrett's esophagus (BE) is a condition in which the normal lining of the esophagus is replaced by abnormal tissue that can increase the risk of esophageal cancer. Endoscopic eradication therapy (EET) removes this abnormal tissue, but most patients need several treatment sessions, leading to higher costs, inconvenience, and cumulative risk. Research suggests that bile reflux, especially a bile acid called deoxycholic acid (DCA), may interfere with healing after treatment by promoting regrowth of Barrett's tissue. Ursodeoxycholic acid (UDCA), an FDA-approved medication used for certain liver and gallbladder conditions, lowers harmful bile acids and may help the normal esophageal lining grow back more effectively. In this pilot study, patients undergoing endoscopic treatment and taking UDCA will be followed to see whether UDCA treatment improves healing and reduces the number of procedures needed. If successful, this approach could lower costs, decrease risks, and make treatment more accessible for patients at risk of esophageal cancer.

Key Dates

First listed

Aug 11, 2026

Start date

Nov 30, 2026

Status verified

Aug 2026

Primary completion

Nov 30, 2027

Completion

Nov 30, 2027

Study Design

Enrollment

15 participants (estimated)

Arms

• Arm: Patients with Barrett's esophagus-associated neoplasia
  Patients with Barrett's esophagus-associated neoplasia who are being treated with UDCA and are undergoing endoscopic eradication therapy

Primary Outcome Measure

Percent Neosquamous Regrowth (PNR) after a single treatment session [ Time Frame: Baseline endoscopy to first follow-up endoscopy at approx. 2 months +/- 4 weeks ]

Central Contacts

• Katharine Godfrey
  6463170740
  [email protected]

Locations (1)

Find similar trials in New York, NY